Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer

Table 3 Univariate analysis of the correlation between clinicopathologic features and overall survival of 142 patients with gastric cancer

Clinicopathologic feature	n	5-yr survival rate (%)	P value1
Gender			0.280
Male	93	44.08
Female	49	38.77
Age (yr)			0.580
< 60	78	41.02
≥ 60	64	43.75
Tumour size (cm)			0.000a
< 5	79	62.02
≥ 5	63	17.46
Borrmann type			0.000a
I + II	33	78.78
III + IV	109	31.19
Histology			0.260
Adenocarcinoma	118	40.67
Others	23	52.17
Differentiation			0.000a
High/moderate	36	69.44
Low/undifferentiated	106	33.01
Tumour invasion			0.000a
T1-2	32	84.37
T3-4	110	30.00
Lymph node metastasis			0.003a
N0-1	54	57.40
N2-3	88	32.95
TNM stage			0.000a
I-II	33	84.84
III-IV	109	29.35
VEGF expression			0.003a
Negative	58	56.89
Positive	84	32.14
VEGFR2 expression			0.000a
Negative	66	68.18
Positive	76	19.73
Endocan-MVD			0.000a
Low	75	64.00
High	67	17.91

¹Log-rank test;

^aP < 0.05, statistically significant. VEGF: Vascular endothelial growth factor; VEGFR2: VEGF receptor 2; MVD: Microvessel density.